Division of Endocrinology, Metabolism and Molecular Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Global Medical Affairs, Ipsen, Boulogne-Billancourt, France.
Adv Ther. 2020 Apr;37(4):1608-1619. doi: 10.1007/s12325-020-01255-8. Epub 2020 Mar 11.
Somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (NETs) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. A new syringe for lanreotide autogel/depot (LAN) was developed following feedback from a human factors study to improve ease of injection compared with previous syringes. PRESTO aimed to assess preferences of nurses between the LAN new syringe and the octreotide long-acting release (LAR) syringe.
PRESTO, a multinational, multicentre, prospective, noninterventional, simulated-use study, enrolled nurses with ≥ 2 years' experience injecting LAN and/or octreotide LAR in patients with NETs and/or acromegaly. Nurses administered injections into pads using the LAN new syringe and octreotide LAR syringe in a randomised sequence. In an anonymous web-based questionnaire, nurses reported their overall preference ('strong' or 'slight'; primary endpoint) and rated and ranked the importance of nine attributes for each syringe (1 [not at all] to 5 [very much]).
Overall, 90 nurses attended sessions and completed valid questionnaires. Most nurses (97.8%) expressed a preference (85.6% 'strong', 12.2% 'slight') for the LAN new syringe versus the octreotide LAR syringe (P < 0.0001). Attribute performance ratings (1 [not at all] to 5 [very much]) were consistently higher for the LAN new syringe versus the octreotide LAR syringe, with the greatest differences in 'fast administration' and 'confidence the syringe will not be clogged' (mean difference [SD]: 2.6 [1.2] and 2.3 [1.5], respectively; P < 0.0001). The attribute ranked most important was 'confidence the syringe will not be clogged' (24.4%); least important was 'convenience of syringe format, including packaging, from preparation to injection' (34.4%).
Nurses preferred the user experience of the LAN new syringe compared with the octreotide LAR syringe, with a particular preference for attributes related to product delivery with the LAN new syringe.
生长抑素类似物被用于治疗神经内分泌肿瘤（NET）和类癌综合征患者的症状和减缓肿瘤进展，并减少肢端肥大症患者的激素分泌和垂体肿瘤体积。一种新的兰瑞肽自动凝胶/长效注射剂（LAN）注射器是在人体因素研究的反馈基础上开发的，旨在提高注射的便利性，与之前的注射器相比。Presto 旨在评估护士对 LAN 新注射器和奥曲肽长效释放（LAR）注射器的偏好。
Presto 是一项多国家、多中心、前瞻性、非干预性、模拟使用研究，招募了具有 NET 和/或肢端肥大症患者 LAN 和/或奥曲肽 LAR 注射经验≥2 年的护士。护士使用 LAN 新注射器和奥曲肽 LAR 注射器在垫上进行随机顺序注射。在匿名的基于网络的问卷中，护士报告了他们对每种注射器的总体偏好（“强烈”或“轻微”；主要终点），并对九个属性的重要性进行了评分和排名（1 [一点也不]至 5 [非常]）。
共有 90 名护士参加了会议并完成了有效问卷。大多数护士（97.8%）表示更喜欢 LAN 新注射器（85.6%“强烈”，12.2%“轻微”）而不是奥曲肽 LAR 注射器（P<0.0001）。属性性能评分（1 [一点也不]至 5 [非常]）始终高于 LAN 新注射器，“快速给药”和“注射器不会堵塞的信心”的差异最大（平均差异[标准差]：2.6 [1.2]和 2.3 [1.5]；P<0.0001）。排名最重要的属性是“注射器不会堵塞的信心”（24.4%）；最不重要的是“注射器格式的便利性，包括从准备到注射的包装”（34.4%）。
护士更喜欢 LAN 新注射器的用户体验，而不是奥曲肽 LAR 注射器，特别喜欢 LAN 新注射器与产品输送相关的属性。
